Industry News
Biotechnology Industry News
Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data
Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data gmasson Wed, 05/11/2022 - 21:55
Caribou ready to uncork the chardonnay thanks to first-in-human CAR-T results
Caribou ready to uncork the chardonnay thanks to first-in-human CAR-T results aarmstrong Wed, 05/11/2022 - 15:19
Former Immunomedics CFO Usama Malik indicted for insider trading, pledging to dispute ‘false and speculative narrative’ at trial
Former Immunomedics CFO Usama Malik indicted for insider trading, pledging to dispute 'false and speculative narrative' at trial gmasson Wed, 05/11/2022 - 13:51
Welcome to new (Bio) Haven: CEO hopes to strike gold twice with remaining R&D crew after Pfizer deal
Welcome to new (Bio) Haven: CEO hopes to strike gold twice with remaining R&D crew after Pfizer deal mbayer Wed, 05/11/2022 - 10:45
Novo Nordisk, Flagship’s forward-thinking partnership aims to treat cardiometabolic, rare diseases
Novo Nordisk, Flagship's forward-thinking partnership aims to treat cardiometabolic, rare diseases gmasson Wed, 05/11/2022 - 10:37
Bioasis, Neuramedy to cross blood-brain barrier together in $72M licensing deal
Bioasis, Neuramedy to cross blood-brain barrier together in $72M licensing deal aarmstrong Wed, 05/11/2022 - 10:23
After failed SPAC and phase 3 fumble, Amicus gene therapy hits another delay to approval
After failed SPAC and phase 3 fumble, Amicus gene therapy hits another delay to approval jwaldron Wed, 05/11/2022 - 09:43
After phase 3 fumble and failed SPAC, Amicus’ Pompe disease drug hits another delay to approval
After phase 3 fumble and failed SPAC, Amicus' Pompe disease drug hits another delay to approval jwaldron Wed, 05/11/2022 - 09:43
Inovio CEO departs, leaving Jacqueline Shea in charge of ‘particularly challenging period’ in the DNA vaccine biotech’s history
Inovio CEO departs, leaving Jacqueline Shea in charge of 'particularly challenging period' in the DNA vaccine biotech's history aarmstrong Wed, 05/11/2022 - 09:30
Inflammation space swells further as Nuvig unveils $47M to transform autoimmune therapies
Inflammation space swells further as Nuvig unveils $47M to transform autoimmune therapies jwaldron Wed, 05/11/2022 - 07:47
Takeda scraps dream of getting rare disease drug to market in latest setback to Wave 1 pipeline
Takeda scraps dream of getting rare disease drug to market in latest setback to Wave 1 pipeline ntaylor Wed, 05/11/2022 - 07:29
Strike 2: Roche flunks another phase 3 lung cancer test to leave TIGIT space reeling
Strike 2: Roche flunks another phase 3 lung cancer test to leave TIGIT space reeling ntaylor Wed, 05/11/2022 - 03:33
Can FDA replicate Operation Warp Speed for rare diseases? Not yet, but Peter Marks has some ideas
Can FDA replicate Operation Warp Speed for rare diseases? Not yet, but Peter Marks has some ideas mbayer Tue, 05/10/2022 - 18:26
Rallybio wades into Sanofi storeroom for $3M rare disease deal
Rallybio wades into Sanofi storeroom for $3M rare disease deal aarmstrong Tue, 05/10/2022 - 12:33
Cortexyme shakes things up with Novosteo acquisition, leadership change and a new name
Cortexyme shakes things up with Novosteo acquisition, leadership change and a new name gmasson Tue, 05/10/2022 - 10:26
Starting gun? $11.6B M&A domino falls as Pfizer scoops up Biohaven for phase 3 migraine nasal spray
Starting gun? $11.6B M&A domino falls as Pfizer scoops up Biohaven for phase 3 migraine nasal spray mbayer Tue, 05/10/2022 - 09:25
Adimab swaps scientist for lawyer as CEO Tillman Gerngross steps down after 15 years
Adimab swaps scientist for lawyer as CEO Tillman Gerngross steps down after 15 years jwaldron Tue, 05/10/2022 - 08:38
Moneybags Nuvation deprioritizes 2 solid tumor prospects to narrow focus onto 3 candidates
Moneybags Nuvation deprioritizes 2 solid tumor prospects to narrow focus onto 3 candidates ntaylor Tue, 05/10/2022 - 08:23
Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indication
Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indication ntaylor Tue, 05/10/2022 - 06:26
Eisai wraps filing for Biogen-partnered Aduhelm followup, hoping to regain ‘credibility and trust’
Eisai wraps filing for Biogen-partnered Aduhelm followup, hoping to regain 'credibility and trust' aarmstrong Mon, 05/09/2022 - 15:54